Checkpoint Inhibitors: New Insights, Indications and Implications for Oncology Research
Full Session Recording
Recently, Linical Accelovance attended the ASCO Annual Meeting, where the best and the brightest minds in cancer research convene each year. While at ASCO, Linical Accelovance hosted a Dine & Discover event with our friends at the Midwest Melanoma Partnership (MMP). This immersive panel discussion took place at Smith & Wollensky's in downtown Chicago and featured renowned cancer experts and Key Opinion Leaders. Topics included:
- The Next Generation - What's next for checkpoint inhibitors
- Clinical Trial Considerations - Preparing for your next oncology study using checkpoint inhibitors
- Trends - Patterns and experiences with current checkpoint inhibitors
- Impacts - How checkpoint inhibitors are expanding into other oncology indications
We invite you to watch the videos, including the full recording above as well as the individual segments below. Have any questions or want to get in touch with us regarding a current / future project? Contact us!
Topic 1: Immune Checkpoint Inhibitors Today: Our Experience in Melanoma
Svetomir N. Markovic, M.D., Ph.D.
Topic 2: What's Coming in the Next Generation of Checkpoint Inhibitors?
Nikhil Khushalani, M.D.
Topic 3: How are Immune Checkpoint Inhibitors Expanding into Other Oncology Indications?
Arek Dudek, M.D., Ph.D.
Topic 4: What Should You Consider Before Starting Your Next Study Involving a Checkpoint Inhibitor?
Jamie Oliver, PharmD & Panel